Abbott Laboratories (ABT)EVP AND GROUP PRESIDENT sold ~$102K

~$102K

Approx. value · 885 sh @ $115.58

146K

Holds after · shares reported

Traded

Mar 2, 2026

Filed

Mar 4, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 23, 2024CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
2. Dec 4, 2025Congress · 1 personMembers of Congress: 2 sales
3. Dec 8, 2025CongressDisclosed sale of ABT — reported range $1,001 - $15,000
4. Dec 18, 2025CongressDisclosed sale of ABT — reported range $1,001 - $15,000
5. Dec 19, 2025CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
6. Jan 22, 2026Company filing · Form 8-K · ResultsReported its results
7. Jan 23, 2026Insider · First insider buy since Feb 2021CEO purchased ~$2.01M of ABT shares in the open market
8. Jan 29, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
9. Feb 4, 2026Insider · 1 personInsiders: 2 purchases (~$1.1M)
10. Feb 10, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
11. Feb 13, 2026FDAFDA device clearance: Armada™ 14 NC PTA Catheter
12. Feb 20, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
13. Feb 23, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
14. Mar 2, 2026 · this disclosureInsiderOfficer sold ~$102K of ABT shares in the open market

What came next

1. Mar 2, 2026Insider · 5 peopleInsiders: 5 sales (~$383K)
2. Mar 9, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
3. Mar 13, 2026FDAFDA device clearance: Amplatzer™ Trevisio™ Intravascular Delivery System; 9-ATV06F45/609-ATV07F45/609-ATV07F45/809-ATV08F45/609-ATV08F45/809-ATV09F45/809-ATV10F45/809-ATV12F45/80
4. Mar 19, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
5. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
6. Apr 16, 2026Company filing · Form 8-K · ResultsReported its results
7. Apr 16, 2026FDAFDA device clearance: Disposable Radiofrequency Cannula
8. Apr 16, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
9. Apr 20, 2026FDAFDA device clearance: EnSite™ X EP System
10. Apr 23, 2026Insider · 1 day before an 8-KCFO purchased ~$201K of ABT shares in the open market
11. Apr 24, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.”
12. Apr 24, 2026FDAFDA device clearance: OPTIS Mobile Next Imaging System (1014932); OPTIS Integrated Next Imaging System (1014933); Ultreon 3.0 Software Upgrade Kit (ULTR300001)
13. Apr 24, 2026FDAFDA device clearance: Amplatzer TorqVue Delivery System
14. Apr 27, 2026Insider · Their largest buy since 2018Director purchased ~$927K of ABT shares in the open market
15. Apr 28, 2026FDAFDA device clearance: Anti-HCV Next
16. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
17. May 7, 2026Insider · Their largest buy since 2019Director purchased ~$174K of ABT shares in the open market
18. May 12, 2026FDARecall: Merlin" Patient Care System (PCS) software Merlin" PCS 3650 programmer Model 3330 software
19. May 12, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
20. May 15, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Abbott Laboratories

For Abbott Laboratories, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 82 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.

Other recent filings by Daniel Gesua Sive Salvadori, EVP AND GROUP PRESIDENT

• SEC Form 4 at Abbott Laboratories (ABT)Feb 1, 2025

The full history of Daniel Gesua Sive Salvadori, EVP AND GROUP PRESIDENT is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Abbott Laboratories

• SEC Form 4Sep 3, 2026
• SEC Form 144Sep 2, 2026
• SEC Form 4Aug 27, 2026
• SEC Form 4Aug 27, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 20, 2026

Everything OQRO holds on this company is on its ABT page.